Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families.
Mahtani MM, Widén E, Lehto M, Thomas J, McCarthy M, Brayer J, Bryant B, Chan G, Daly M, Forsblom C, Kanninen T, Kirby A, Kruglyak L, Munnelly K, Parkkonen M, Reeve-Daly MP, Weaver A, Brettin T, Duyk G, Lander ES, Groop LC. Mahtani MM, et al. Among authors: brayer j. Nat Genet. 1996 Sep;14(1):90-4. doi: 10.1038/ng0996-90. Nat Genet. 1996. PMID: 8782826
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.
Sudalagunta PR, Canevarolo RR, Meads MB, Silva M, Zhao X, Cubitt CL, Sansil SS, DeAvila G, Alugubelli RR, Bishop RT, Tungesvik A, Zhang Q, Hampton O, Teer JK, Welsh EA, Yoder SJ, Shah BD, Hazlehurst L, Gatenby RA, Van Domelen DR, Chai Y, Wang F, DeCastro A, Bloomer AM, Siegel EM, Lynch CC, Sullivan DM, Alsina M, Nishihori T, Brayer J, Cleveland JL, Dalton W, Walker CJ, Landesman Y, Baz R, Silva AS, Shain KH. Sudalagunta PR, et al. Among authors: brayer j. Cancer Res. 2024 Oct 30. doi: 10.1158/0008-5472.CAN-24-0886. Online ahead of print. Cancer Res. 2024. PMID: 39476082
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.
Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Freeman CL, et al. Among authors: brayer j. Clin Cancer Res. 2023 Nov 14;29(22):4575-4585. doi: 10.1158/1078-0432.CCR-22-3987. Clin Cancer Res. 2023. PMID: 37735756
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier C, Blue BJ, Brayer J, Chandrasekhar S, Grajales Cruz A, De Avila G, Elmariah H, Faramand R, Freeman C, Jain M, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Lee DH, et al. Among authors: brayer j. Blood Adv. 2023 Aug 22;7(16):4247-4257. doi: 10.1182/bloodadvances.2023009766. Blood Adv. 2023. PMID: 37307173 Free PMC article.
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A. Sallman DA, et al. Among authors: brayer jb. Lancet Haematol. 2023 Mar;10(3):e191-e202. doi: 10.1016/S2352-3026(22)00378-7. Epub 2023 Feb 7. Lancet Haematol. 2023. PMID: 36764323 Clinical Trial.
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, Gonzalez RM, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova OV, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue BJ, Grajales-Cruz AF, Castaneda Puglianini OA, Liu HD, Nishihori T, Freeman CL, Brayer JB, Shain KH, Baz RC, Locke FL, Alsina M, Sidana S, Hansen DK. Logue JM, et al. Among authors: brayer jb. Blood Adv. 2022 Dec 27;6(24):6109-6119. doi: 10.1182/bloodadvances.2022008320. Blood Adv. 2022. PMID: 35939783 Free PMC article.
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Zhang Y, et al. Among authors: brayer j. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e770-e776. doi: 10.1016/j.clml.2022.04.003. Epub 2022 Apr 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35504808 Free PMC article.
Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma.
Peres LC, Colin-Leitzinger CM, Teng M, Dutil J, Alugubelli RR, DeAvila G, Teer JK, Du D, Mo Q, Siegel EM, Hampton OA, Alsina M, Brayer J, Blue B, Baz R, Silva AS, Nishihori T, Shain KH, Gillis N. Peres LC, et al. Among authors: brayer j. Blood Adv. 2022 Jun 28;6(12):3767-3778. doi: 10.1182/bloodadvances.2021006652. Blood Adv. 2022. PMID: 35500227 Free PMC article.
63 results